Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
7.4
5.2
Journals
Cancers
Special Issues
Breast Cancer Metastasis: Novel Insights into Molecular Mechanisms and Treatments
share announcement

Special Issue "Breast Cancer Metastasis: Novel Insights into Molecular Mechanisms and Treatments"

A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Metastasis".

Deadline for manuscript submissions: 10 April 2024 | Viewed by 2363

Special Issue Editor

Dr. Delphine Denoyer

E-Mail Website
Guest Editor
Matrix Microenvironment & Metastasis Laboratory, Translational Breast Cancer Program, Olivia Newton-John Cancer Research Institute, Melbourne, Australia
Interests: breast cancer; metastasis; ferroptosis; tyrosine kinase inhibitors; extracellular matrix; integrins; molecular imaging (PET and SPECT, high resolution autoradiography); radionuclide therapy; metallomics

Special Issue Information

Dear Colleagues,

Breast cancer has become the most diagnosed cancer worldwide with about 685,000 deaths recorded in 2020. Metastases are responsible for approximately 90% of breast cancer-related deaths and, despite treatment advances, they remain largely incurable. Breast cancer preferentially metastasizes to bones, lungs, liver, and brain. However, molecular features dictating site-specific metastasis and differential responses to therapy are still poorly understood. Therefore, a better comprehension of how metastatic breast cancer cells interact with their microenvironment is essential for the design of tailored treatments.

We are pleased to invite you to contribute to this Special Issue entitled “Breast Cancer Metastasis: Novel Insights into Molecular Mechanisms and Treatments” that aims to provide the latest key findings in the field of basic and translational research on metastatic breast cancer. In this Special Issue, original research articles and reviews are welcome. Research areas may include (but are not limited to) the following: cellular and molecular mechanisms regulating organ-specific metastasis and tumor dormancy, biomarker discovery, and advancements in therapeutic approaches for the various breast cancer subtypes, including small-molecule inhibitors and immunotherapy.

We look forward to receiving your contributions.

Dr. Delphine Denoyer
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • breast cancer
  • metastasis
  • organ-specific metastasis
  • cellular and molecular mechanisms
  • biomarkers
  • response to treatments
  • small-molecule inhibitors
  • immunotherapy
  • tumor dormancy

Published Papers (2 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

get_app
Article
PTHrP Regulates Fatty Acid Metabolism via Novel lncRNA in Breast Cancer Initiation and Progression Models
by
Rui Zhang
,
Jiarong Li
,
Dunarel Badescu
,
Andrew C. Karaplis
,
Jiannis Ragoussis
and
Richard Kremer
Cancers 2023, 15(15), 3763; https://doi.org/10.3390/cancers15153763 - 25 Jul 2023
Viewed by 581
Abstract
Parathyroid hormone-related peptide (PTHrP) is the primary cause of malignancy-associated hypercalcemia (MAH). We previously showed that PTHrP ablation, in the MMTV-PyMT murine model of breast cancer (BC) progression, can dramatically prolong tumor latency, slow tumor growth, and prevent metastatic spread. However, the signaling [...] Read more.
Parathyroid hormone-related peptide (PTHrP) is the primary cause of malignancy-associated hypercalcemia (MAH). We previously showed that PTHrP ablation, in the MMTV-PyMT murine model of breast cancer (BC) progression, can dramatically prolong tumor latency, slow tumor growth, and prevent metastatic spread. However, the signaling mechanisms using lineage tracing have not yet been carefully analyzed. Here, we generated Pthrpflox/flox; Cre+ mT/mG mice (KO) and Pthrpwt/wt; Cre+ mT/mG tumor mice (WT) to examine the signaling pathways under the control of PTHrP from the early to late stages of tumorigenesis. GFP+ mammary epithelial cells were further enriched for subsequent RNA sequencing (RNAseq) analyses. We observed significant upregulation of cell cycle signaling and fatty acid metabolism in PTHrP WT tumors, which are linked to tumor initiation and progression. Next, we observed that the expression levels of a novel lncRNA, GM50337, along with stearoyl-Coenzyme A desaturase 1 (Scd1) are significantly upregulated in PTHrP WT but not in KO tumors. We further validated a potential human orthologue lncRNA, OLMALINC, together with SCD1 that can be regulated via PTHrP in human BC cell lines. In conclusion, these novel findings could be used to develop targeted strategies for the treatment of BC and its metastatic complications. Full article
(This article belongs to the Special Issue Breast Cancer Metastasis: Novel Insights into Molecular Mechanisms and Treatments)
►▼ Show Figures

Figure 1

get_app
Article
Loco-Regional Treatment of the Primary Tumor in De Novo Metastatic Breast Cancer Patients Undergoing Front-Line Chemotherapy
by
Corrado Tinterri
,
Andrea Sagona
,
Erika Barbieri
,
Simone Di Maria Grimaldi
,
Flavia Jacobs
,
Alberto Zambelli
,
Rubina Manuela Trimboli
,
Daniela Bernardi
,
Valeriano Vinci
and
Damiano Gentile
Cancers 2022, 14(24), 6237; https://doi.org/10.3390/cancers14246237 - 17 Dec 2022
Viewed by 1187
Abstract
Background: Loco-regional therapy (LRT) in de novo metastatic breast cancer (MBC) has been investigated in several clinical trials, with heterogeneous and conflicting results. Methods: We conducted a retrospective study of de novo MBC patients treated with front-line chemotherapy (FLC) followed by LRT of [...] Read more.
Background: Loco-regional therapy (LRT) in de novo metastatic breast cancer (MBC) has been investigated in several clinical trials, with heterogeneous and conflicting results. Methods: We conducted a retrospective study of de novo MBC patients treated with front-line chemotherapy (FLC) followed by LRT of the primary tumor. Our aims were to evaluate the characteristics, treatment, and oncological outcomes in terms of progression-free survival (PFS), distant progression-free survival (DPFS), and overall survival (OS) of de novo MBC. We also investigated possible subgroups of patients with better outcomes according to menopausal status, biological sub-type, location, number of metastases, and radiologic complete response after FLC. Results: We included 61 patients in the study. After a median follow-up of 55 months, disease progression occurred in 60.7% of patients and 49.2% died. There were no significant differences in PFS, DPFS, and OS between different subgroups of de novo MBC patients. A trend toward better PFS and DPFS was observed in triple-positive tumors, without a statistically significant difference in OS. Conclusions: No specific subgroup of de novo MBC patients showed a statistically significant survival advantage after FLC followed by LRT of the primary tumor. Full article
(This article belongs to the Special Issue Breast Cancer Metastasis: Novel Insights into Molecular Mechanisms and Treatments)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-2
Back to TopTop